Xbiome, an AI-driven microbiome therapeutics company, has acquired the clinical-stage M201 program from Assembly Biosciences, a clinical-stage biotechnology company developing innovative therapeutics ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Xbiome Inc., an industry leading AI driven microbiome therapeutics company, today announced that it has acquired the clinical-stage M201 program from Assembly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results